7 Key Events That Solidified the Liquid Biopsy Market

Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.

  • Rise of the Liquid Biopsy Market

    Liquid Biopsies are non-invasive alternatives to surgical biopsies and allow physicians to discover information about a disease or condition through a liquid sample. The market has seen tremendous growth over the past few years with several memorable events that include, blockbuster deals, mammoth financings, and significant FDA approvals. Here are the key events in recent history that have helped solidify the Liquid Biopsy market.

    Pixabay
  • Roche Receives FDA Nod for Lung Cancer Detection Test

    Nothing screams validation like an FDA approval for a diagnostic. In 2016, Roche received one of the first FDA approvals for cobas EGFR Mutation Test v2, which can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. The test is intended as a companion diagnostic test for the cancer drug Tarceva.

    Pixabay
  • Trovagene Goes For A Different Kind of Liquid Biopsy Test

    We often associate blood with liquid biopsy test. But San Diego, CA-based Trovagene went for a different liquid when developing its assay to detect and monitor cancer – urine. The company changed the paradigm and proved a patient’s blood isn’t the only liquid sample you can test. It also made the company stand out from other traditional liquid biopsy firms. 

     

     

    Pixabay
  • Qiagen’s Groundbreaking Collaborations

    Three years ago, Qiagen partnered with Astrazeneca to develop a lung cancer combination diagnostic called therascreenEGFRRGQ Plasma PCR kit.  A few months ago, Qiagen found another partner in San Carlos, CA-based Natera. But instead of developing a test for cancer, the Hilden, Germany-based company worked on a noninvasive prenatal test with Natera. Qiagen noted this was the first time it ventured into this space. The high profile partnerships not only raised the profile of liquid biopsies, but also reminded people that cancer wasn't the only thing the assays could test for. 

    Pixabay
  • Liquid Biopsy Companies Bring in Record-Breaking Funding

    In the medtech or diagnostics industry, you’re doing pretty good if you can get a over $30 million dollars in a financing round. But when it comes to liquid biopsy – the amount has been anything from Exact Sciences recent $52 million series E round, to Grail’s whopping $900 million in its second financing round. Investors are betting big on liquid biopsy. The level of funding shows not only the commitment of investors, but the trust they have in these tests leading to a change in the cancer detection paradigm.

    Pixabay
  • Guardant Health Files IPO

    Guardant Health was founded in 2012 by Helmy Eltoukhy Phd, and AmirAli Talasaz, PhD. The Redwood City, CA-based company announced earlier this month that it was seeking to raise $100 million through a public offering. The firm has performed solidly and raised $360 million in May of 2017.

    Pixabay
  • Roche Acquires Foundation Medicine

    All that’s missing from this list is a high profile acquisition in the space. And through Roche we’ve got one. The Basel, Switzerland-based company paid $2.4 billion to acquire Foundation Medicine. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January 2015 when Roche invested roughly $1.03 billion to acquire a majority interest in Foundation Medicine.  The Cambridge, MA-based company has developed FoundationOneLiquid, a liquid biopsy test provides targeted gene and microsatellite instability  results that can help direct therapy selection and clinical trial options for advanced-stage cancer patients.

    Pixabay
  • Illumina Spins off Grail

    In January of 2016, Illumina, one of the largest DNA sequencing companies, has announced the formation of a startup known as Grail. The newly form company was launched on a $100 million series A round (WOW). About a year later, Grail raised enough funds to become independent of Illumina. The news surrounding Grail grabbed headlines and garnered a great deal of attention. It also set off a chain of events and raised the bar for financings in the liquid biopsy space. Grail is focused on validation of blood tests for early-stage cancer detection, including the its Circulating Cell-free Genome Atlas (CCGA) study and other large-scale clinical trials that are expected to enroll hundreds of thousands of patients. The CCGA study will characterize the landscape of cell-free DNA profiles in individuals with cancer and in healthy non-cancer participants using Grail's high-intensity (ultra-broad and ultra-deep) sequencing approach.

    Pixabay
Filed Under
500 characters remaining